Administration of the mitochondria-targeted anti-oxidant mitoquinone significantly decreased plasma ALT and aspartate aminotransferase in patients with chronic HCV infection, and this suggests that mitoquinone may decrease necroinflammation in the liver in these patients. As mitochondrial oxidative damage contributes to many other chronic liver diseases, such as steatohepatitis, further studies using mitochondria-targeted anti-oxidants in HCV and other liver diseases are warranted.

No abstract

The effects of pretransplant obesity, diabetes mellitus (DM), coronary artery disease (CAD), and hypertension (HTN) on outcomes after liver transplantation (LT) are controversial. Questions have also been raised about the appropriateness of the body mass index (BMI) for assessing obesity in patients with end-stage liver disease. Both issues have implications for organ allocation in LT. To address these questions, we undertook a cohort study of 202 consecutive patients (2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)(2010) undergoing LT at a national center in New Zealand. BMI and body fat percentage (%BF) values (dual-energy X-ray absorptiometry) were measured before transplantation, and the methods were compared. The influence of pretransplant risk variables (including obesity, DM, CAD, and HTN) on the 30-day postoperative event rate, length of hospital stay, and survival were analyzed. There was agreement between the calculated BMI and the measured %BF for 86.0% of the study population (j coefficient 5 0.73, 95% confidence interval 5 0.61-0.85), and this was maintained across increasing Model for EndStage Liver Disease scores. Obesity was an independent risk factor for the postoperative event rate [count ratio (CR) 5 1.03, P < 0.001], as was DM (CR 5 1.4, P < 0.001). Obesity with concomitant DM was the strongest predictor of the postoperative event rate (CR 5 1.75, P < 0.001) and a longer hospital stay (5.81 days, P < 0.01). Independent metabolic risk factors had no effect on 30-day, 1-year, or 5-year patient survival. In conclusion, BMI is an adequate tool for assessing obesity-associated risk in LT. Early post-LT morbidity is highest for patients with concomitant obesity and DM, although these factors do not appear to influence recipient survival. Liver Transpl 20:281-290, 2014. V C 2014 AASLD.

No abstract

Readability is a crucial presentation attribute that web summarization algorithms consider while generating a querybaised web summary. Readability quality also forms an important component in real-time monitoring of commercial search-engine results since readability of web summaries impacts clickthrough behavior, as shown in recent studies, and thus impacts user satisfaction and advertising revenue.The standard approach to computing the readability is to first collect a corpus of random queries and their corresponding search result summaries, and then each summary is then judged by a human for its readabilty quality. An average readability score is then reported. This process is time consuming and expensive. Besides, the manual evaluation process can not be used in the real-time summary generation process. In this paper we propose a machine learning approach to the problem. We use the corpus as described above and extract summary features that we think may characterize readability. We then estimate a model (gradient boosted decision tree) that predicts human judgments given the features. This model can then be used in real time to estimate the readability of new (unseen) web search summaries and also be used in the summary generation process.We present results on approximately 5000 editorial judgments collected over the course of a year and show examples where the model predicts the quality well and where it disagrees with human judgments. We compare the results of the model to previous models of readability, most notably Collins-Thompson-Callan, Fog and Flesch-Kincaid, and see that our model shows substantially better correlation with editorial judgments as measured by Pearson's correlation coefficient. The learning algorithm also provides us with the relative importance of the features used.

No abstract

Interferon (IFN)-free, direct-acting antiviral (DAA) therapy agents provide a safe and efficacious treatment for liver transplant recipients with recurrent hepatitis C virus (HCV) infection. The aim of this study is to evaluate the impact of HCV eradication on the metabolic factors in liver transplant recipients. We completed a retrospective single-center study on HCV-related liver transplant recipients treated with IFN-free DAAs including both treatment-naive and treatment-experienced patients. IFN-free DAAs impact on the metabolic profile were assessed at baseline and sustained virological response (SVR) between 24 and 48 weeks. In total, 91 liver transplant recipients with recurrent HCV infection received IFN-free DAA treatment, 62 patients had IFN-based treatment failure, and 29 were treatment-naïve, of whom 87 (96%) achieved SVR. Eradication of recurrent HCV infection was associated with reduction in the treatment of diabetes and hypertension by 38% and 22% from the baseline respectively. Hemoglobin A1c (HbA1c) levels declined from mean 35.5 ± 4.3 mmol/mol to 33.3 ±3.6 mmol/mol at 44 weeks posttreatment (P = 0.03). Total cholesterol levels increased from 3.8 ± 0.9 mmol/L to 4.9 ± 0.9 mmol/L at 41 weeks posttreatment (P < 0.0001), reflecting a significant increase in serum low-density lipoprotein (LDL) levels (2.0 ± 0.8 to 2.9 ± 0.8; P < 0.0001). Estimated glomerular filtration rate (eGFR) levels increased from 64.9 ± 20 mL/minute to 69.6 ± 20 mL/minute at 24 weeks posttreatment (P = 0.0004). Glucose, lipid profile, and eGFR changes were independent of weight changes and immunosuppression dosage and trough levels. In conclusion, eradication of recurrent HCV infection by DAA therapy has beneficial impacts on glucose metabolism and renal profile and reverses the hypolipidemic effect of HCV in liver transplant recipients. These extrahepatic effects of DAA therapy need to be validated by larger prospective studies.

JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact